II. Wissenschaftliche Vorträge

Tsujimoto, Y, Finger, L. R., Yunis, J., Nowcll, P C., Croce, C. M., Cloningofthe chromoso-
me breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science.
1984 Nov 30; 226 (4678): 1097-9.
Tsujimoto, Y, Cossman, J., Jaffe, E., Croce, C. M., Involvement of the Bcl-2 gene in human
follicular lymphoma. Science. 1985 Jun 21; 228 (4706): 1440—3.
Groffen, J., Stephenson, J. R., Heisterkamp, N., de Klein, A., Bartram, C. R., Grosveld G.
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on
chromosome 22. Cell. 1984Jan; 36 (1): 93 — 9.
Rudkin, C. T, Hungerford DA, Nowell PC. DNA contents of chromosome Phi and
chromosome 21 in human chronic granulocytic leukemia. Science. 1964 Jun 144 (3623):
1229-31.
Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Möller, P, Falk, W, Debatin, K. M., Kram-
mer, P H., Monoclonal antibody-mediated tumor regression by induction of apoptosis.
Science. 1989 Jul 21; 245 (4915): 301-5.
Debatin, K. M., Goldmann, C. K., Bamford, R., Waldmann, T. A., Krammer, P H., Mono-
clonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet. 1990 Mar 3; 335
(8688): 497-500.
Friesen, C., Herr, I., Krammer, P H., Debatin, K. M., Involvement of the CD95 (APO-1/
FAS) receptor/ligand System in drug-induced apoptosis in leukemia cells. Nat Med. 1996
May; 2 (5): 574-7.
Fulda, S., Wick, W, Weller, M., Debatin, K. M., Smac agonists sensitize for Apo2L/TRAIL-
or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Nat Med. 2002 8 (8), 808-815.
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A.,
Seto, Y, Nagata, S., The polypeptide encoded by the cDNA for human cell surface anti-
gen Fas can mediate apoptosis. Cell. 1991 Jul 26; 66 (2): 233 — 43.
Roberts, A.W, Davids, M. S., Pagel, J. M., Kahl, B. S., Puwada, S. D., Gerecitano, J. E,
Kipps, T.J., Anderson, M. A., Brown, J. R., Gressick, L., Wong, S., Dunbar, M., Zhu, M.,
Desai, M. B., Cerri, E., Heitner Enschede, S., Humerickhouse, R. A., Wierda, W. G., Sey-
mour, J. E, Targeting Bcl-2 with Venetoclax in relapsed chronic lymphocytic leukemia. N
EngiJMed. 2016 374 (4), 311-22.
Hanahan, D., Weinberg, R. A., Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;
144 (5): 646-74
Meyer, L. H., Eckhoff, S. M., Queudeville, M., Kraus, J. M., Giordan, M., Stursberg, J.,
Zangrando, A., Vendramini, E., Möricke, A., Zimmermann, M., Schrauder, A., Lahr, G.,
Holzmann, K., Schrappe, M., Basso, G., Stahnke, K., Kestler, H. A., Te Kronnie, G., De-
batin, K. M., Early relapse in ALL is identified by time to leukemia in NOD/SCID mice
and is characterized by a gene signature involving survival pathways. Cancer Cell. 2011 19
(2), 206-217.
Seyfried, E, Demir, S., Höri, R. L., Stirnweiss, F. U., Ryan, J., Scheffold, A., Villalobos-
Ortiz, M., Boldrin, E., Zinngrebe, J., Enzenmüller, S.,Jenni, S., Tsai, Y.C., Bornhauser,
B., Fürstberger, A., Kraus, J. M., Kestler, H. A., Bourquin, J. P, Stilgenbauer, S., Letai, A.,
Debatin, K. M., Meyer, L. H., Prediction of venetoclax activity in precursor B-ALL by
functional assessment of apoptosis signaling. Cell Death Dis. 2019 10 (8), 571.

64